Drugs /

incomplete freund's adjuvant

Back to Drugs List

Overview

NCI Definition [1]:
A water-in-oil emulsion that stimulates the T-cell immune response to antigens and may be used in various types of cancer vaccines. (NCI04)

Clinical Trials

View Clinical Trials for incomplete freund's adjuvant

Incomplete freund's adjuvant has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating incomplete freund's adjuvant, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open).

HLA-A*02 Positive, HLA-A*03 Positive, and BIRC5 Expression are the most frequent biomarker inclusion criteria for incomplete freund's adjuvant clinical trials.

Melanoma, gastrointestinal neuroendocrine tumors, and lung neuroendocrine neoplasm are the most common diseases being investigated in incomplete freund's adjuvant clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Incomplete Freund's Adjuvant
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating incomplete freund's adjuvant and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
7103, montanide isa 51, 7474, 8652, 675756, 6123, ifa, incomplete freund's adjuvant, 5924, freund's incomplete adjuvant, montanide isa-51, montanide isa 51, 11152, 8709, freund's incomplete adjuvant, isa-51, 11024
NCIT ID [1]:
C1573

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.